May 10, 2017 06:16 AM EDT

In a stunning setback, Roche says its top cancer drug Tecentriq failed a key PhIII study

John Carroll

Editor & Founder

Genentech put the A team on their PD-L1 checkpoint program for Tecentriq (atezolizumab), building a pipeline of combinations now in the clinic as they …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

In a stunning setback, Roche says its top cancer drug Tecentriq failed a key PhIII study

John Carroll

Editor & Founder

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Trump’s science crackdown hits rare disease research: ‘We need to sit down with Elon Musk’

At least seven drugmakers say they will participate in round two of IRA negotiations

Exclusive: Infectious disease doctors consider 'mini-ACIP' if RFK erodes CDC vaccine panel

Lilly joins molecular glue field with Magnet deal worth up to $1.25B

Where the money is: The top 100 venture investors in biotech

How AI can address ongoing challenges in the life sciences industry

In a stun­ning set­back, Roche says its top can­cer drug Tecen­triq failed a key PhI­II study

Editor & Founder

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

In a stunning setback, Roche says its top cancer drug Tecentriq failed a key PhIII study